Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level

Recombinant human interleukin‐2 (rIL‐2) was administered to 34 patients with advanced malignancy. Three schedules of rIL‐2 administration employed were as follows: (A) 2‐hr iv infusion of 6.7 × 10(*5) U/m(*2)/day (A(1), 6 cases) or 2.2 × 10(*6) U/m(*2)/day (A(2), 8 cases) for five consecutive days;...

Descripción completa

Detalles Bibliográficos
Autores principales: Sano, Tetsuro, Saijo, Nagahiro, Sasaki, Yasutsuna, Shinkai, Tetsu, Eguchi, Kenji, Tamura, Tomohide, Sakurai, Masanori, Takahashi, Hidenobu, Nakano, Hidehiko, Nakagawa, Kazuhiko, Hong, Weon‐Seon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1988
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907760/
https://www.ncbi.nlm.nih.gov/pubmed/3128501
http://dx.doi.org/10.1111/j.1349-7006.1988.tb00020.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907760/
https://www.ncbi.nlm.nih.gov/pubmed/3128501
http://dx.doi.org/10.1111/j.1349-7006.1988.tb00020.x

Ejemplares similares